Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: The treatment of melanoma has been significantly improved by immune checkpoint blockade (ICB); however, primary immune resistance, particularly in PD-L1-negative tumors and in selected treatment contexts, remains a critical efficacy bottleneck. Traditional biomarkers show clear limitations in explaining resistance mechanisms and guiding clinical stratification.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
